Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Florida-based AP governance firm selected as an RFP-stage contender, reinforcing its leadership in SAP vendor and customer master data compliance, modernization, and enterprise AP controls. PORT ST.

Jerome Dorlack (President, CEO & Director) said Q2 was a “solid performance” and that results were “in line with our expectations,” citing “typical seasonality in China and some temporary production ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. Analysis: The Hormuz Hit to Helium Create an FP account ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...

Italy awarded a €211 million ($249 million) grant to a company seeking to speed up processing at artificial intelligence data centers as part of a bid to support local startups. 2D Photonics Group’s ...